Literature DB >> 23400849

(99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses.

Sabahat Bokhari1, Adam Castaño, Ted Pozniakoff, Susan Deslisle, Farhana Latif, Mathew S Maurer.   

Abstract

BACKGROUND: Differentiating immunoglobulin light-chain (AL) from transthyretin-related cardiac amyloidoses (ATTR) is imperative given implications for prognosis, therapy, and genetic counseling. We validated the discriminatory ability of (99m)Tc-pyrophosphate ((99m)Tc-PYP) scintigraphy in AL versus ATTR. METHODS AND
RESULTS: Forty-five subjects (12 AL, 16 ATTR wild type, and 17 ATTR mutants) underwent (99m)Tc-PYP planar and single-photon positive emission computed tomography cardiac imaging. Scans were performed by experienced nuclear cardiologists blinded to the subjects' cohort assignment. Cardiac retention was assessed with both a semiquantitative visual score (range, 0; no uptake to 3, diffuse uptake) and by quantitative analysis by drawing a region of interest over the heart corrected for contralateral counts and calculating a heart-to-contralateral ratio. Subjects with ATTR cardiac amyloid had a significantly higher semiquantitative cardiac visual score than the AL cohort (2.9±0.06 versus 0.8±0.27; P<0.0001) as well as a higher quantitative score (1.80±0.04 versus 1.21±0.04; P<0.0001). Using a heart-to-contralateral ratio >1.5 consistent with intensely diffuse myocardial tracer retention had a 97% sensitivity and 100% specificity with area under the curve 0.992, P<0.0001 for identifying ATTR cardiac amyloidosis.
CONCLUSIONS: (99m)Tc-PYP cardiac imaging distinguishes AL from ATTR cardiac amyloidosis and may be a simple, widely available method for identifying subjects with ATTR cardiac amyloidosis, which should be studied in a larger prospective manner.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23400849      PMCID: PMC3727049          DOI: 10.1161/CIRCIMAGING.112.000132

Source DB:  PubMed          Journal:  Circ Cardiovasc Imaging        ISSN: 1941-9651            Impact factor:   7.792


  34 in total

1.  Myocardial Tc-99m MDP uptake on a bone scan in senile systemic amyloidosis with cardiac involvement.

Authors:  I Ak; E Vardareli; O Erdinĉ; E Kasapoğlu; N Ata
Journal:  Clin Nucl Med       Date:  2000-10       Impact factor: 7.794

2.  Technetium stannous pyrophosphate myocardial scintigrams in patients with chest pain of varying etiology.

Authors:  J T Willerson; R W Parkey; F J Bonte; S L Meyer; J M Atkins; E M Stokley
Journal:  Circulation       Date:  1975-06       Impact factor: 29.690

3.  Scanning for soft-tissue amyloid.

Authors:  R W Kula; W K Engel; B R Line
Journal:  Lancet       Date:  1977-01-08       Impact factor: 79.321

4.  Binding of serum amyloid P-component (SAP) by amyloid fibrils.

Authors:  M B Pepys; R F Dyck; F C de Beer; M Skinner; A S Cohen
Journal:  Clin Exp Immunol       Date:  1979-11       Impact factor: 4.330

5.  Non-invasive assessment of the presence and severity of cardiac amyloidosis. A study in familial amyloidosis with polyneuropathy by cross sectional echocardiography and technetium-99m pyrophosphate scintigraphy.

Authors:  P Eriksson; C Backman; P Bjerle; A Eriksson; S Holm; B O Olofsson
Journal:  Br Heart J       Date:  1984-09

6.  Sensitivity of technetium-99m-pyrophosphate scintigraphy in diagnosing cardiac amyloidosis.

Authors:  R H Falk; V W Lee; A Rubinow; W B Hood; A S Cohen
Journal:  Am J Cardiol       Date:  1983-03-01       Impact factor: 2.778

7.  Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis.

Authors:  Helen J Lachmann; David R Booth; Susanne E Booth; Alison Bybee; Janet A Gilbertson; Julian D Gillmore; Mark B Pepys; Philip N Hawkins
Journal:  N Engl J Med       Date:  2002-06-06       Impact factor: 91.245

8.  Value of positive myocardial technetium-99m-pyrophosphate scintigraphy in the noninvasive diagnosis of cardiac amyloidosis.

Authors:  T A Wizenberg; J Muz; Y H Sohn; W Samlowski; A M Weissler
Journal:  Am Heart J       Date:  1982-04       Impact factor: 4.749

9.  [Cardiac involvement in systemic amyloidosis: myocardial scintigraphic evaluation].

Authors:  M Hongo; H Yamada; S Okubo; J Hirayama; T Fujii; S Kusama; S Ikeda
Journal:  J Cardiogr       Date:  1985-03

10.  Tabulation of human transthyretin (TTR) variants, 2003.

Authors:  Lawreen Heller Connors; Amareth Lim; Tatiana Prokaeva; Violet A Roskens; Catherine E Costello
Journal:  Amyloid       Date:  2003-09       Impact factor: 7.141

View more
  151 in total

1.  Role of imaging in cardiac amyloidosis: An ongoing challenge.

Authors:  Ashutosh D Wechalekar
Journal:  J Nucl Cardiol       Date:  2015-11-05       Impact factor: 5.952

2.  Expanding the Horizons of Nuclear Cardiology: Disease Management.

Authors:  David Wolinsky
Journal:  J Nucl Cardiol       Date:  2015-10       Impact factor: 5.952

3.  PET Detection of Cerebral Necrosis Using an Infarct-Avid Agent 2-Deoxy-2-[18F]Fluoro-D-Glucaric Acid (FGA) in a Mouse Model of the Brain Stroke.

Authors:  Hailey Houson; Alexander Mdzinarishvili; Hariprasad Gali; Evgeny Sidorov; Vibhudutta Awasthi
Journal:  Mol Imaging Biol       Date:  2020-10       Impact factor: 3.488

Review 4.  Imaging of Left Ventricular Hypertrophy: a Practical Utility for Differential Diagnosis and Assessment of Disease Severity.

Authors:  Toru Kubo; Hiroaki Kitaoka
Journal:  Curr Cardiol Rep       Date:  2017-08       Impact factor: 2.931

5.  Estimating cancer risk from 99mTc pyrophosphate imaging for transthyretin cardiac amyloidosis.

Authors:  Andrew J Einstein; Igor Shuryak; Adam Castaño; Akiva Mintz; Mathew S Maurer; Sabahat Bokhari
Journal:  J Nucl Cardiol       Date:  2018-05-30       Impact factor: 5.952

Review 6.  Role of Imaging in Evaluating Infiltrative Heart Disease.

Authors:  Sanjay Divakaran; Avinainder Singh; Bradley Collins; Tomas Vita; Rodney H Falk; Marcelo F Di Carli; Ron Blankstein
Journal:  Curr Treat Options Cardiovasc Med       Date:  2017-01

7.  Cardiac amyloidosis is prevalent in older patients with aortic stenosis and carries worse prognosis.

Authors:  João L Cavalcante; Shasank Rijal; Islam Abdelkarim; Andrew D Althouse; Michael S Sharbaugh; Yaron Fridman; Prem Soman; Daniel E Forman; John T Schindler; Thomas G Gleason; Joon S Lee; Erik B Schelbert
Journal:  J Cardiovasc Magn Reson       Date:  2017-12-07       Impact factor: 5.364

8.  Efficient 1-Hour Technetium-99 m Pyrophosphate Imaging Protocol for the Diagnosis of Transthyretin Cardiac Amyloidosis.

Authors:  Ahmad Masri; Syed Bukhari; Shahzad Ahmad; Ricardo Nieves; Yvonne S Eisele; William Follansbee; Amy Brownell; Timothy C Wong; Erik Schelbert; Prem Soman
Journal:  Circ Cardiovasc Imaging       Date:  2020-02-17       Impact factor: 7.792

9.  Can 99mTc-Pyrophosphate Aid in Early Detection of Cardiac Involvement in Asymptomatic Variant TTR Amyloidosis?

Authors:  Muhammad Haq; Sumeet Pawar; John L Berk; Edward J Miller; Frederick L Ruberg
Journal:  JACC Cardiovasc Imaging       Date:  2016-08-24

Review 10.  Wild-Type Transthyretin Cardiac Amyloidosis: Novel Insights From Advanced Imaging.

Authors:  David L Narotsky; Adam Castano; Jonathan W Weinsaft; Sabahat Bokhari; Mathew S Maurer
Journal:  Can J Cardiol       Date:  2016-05-13       Impact factor: 5.223

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.